Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)

被引:0
|
作者
Ono, Tomohiro [1 ,2 ]
Uto, Megumi [2 ]
Mineharu, Yohei [3 ]
Arakawa, Yoshiki [3 ]
Nakamura, Mitsuhiro [4 ]
Nishio, Teiji [5 ]
Igaki, Hiroshi [6 ]
Nihei, Keiji [7 ]
Ishikura, Satoshi [8 ]
Narita, Yoshitaka [9 ]
Mizowaki, Takashi [2 ]
Brain Tumor Study Grp
Radiat Therapy Study Grp
Japan Clin Oncol Grp
机构
[1] Shiga Gen Hosp, Dept Radiat Oncol, Shiga, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Adv Med Phys, Kyoto, Japan
[5] Osaka Univ, Grad Sch Med, Med Phys Lab, Div Hlth Sci, Osaka, Japan
[6] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan
[7] Osaka Med & Pharmaceut Univ, Dept Radiat Oncol, Osaka, Japan
[8] St Lukes Int Univ, St Lukes Int Hosp, Dept Radiat Oncol, Tokyo, Japan
[9] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan
关键词
Dummy run study; Elderly patients with newly diagnosed glioblastoma; JCOG1910; Outlining; RANDOMIZED PHASE-III; RADIATION-THERAPY; DOSE CALCULATION; NORMAL TISSUE; TEMOZOLOMIDE; CONCOMITANT; ASSURANCE; ADJUVANT; IMPACT; OLDER;
D O I
10.1186/s13014-025-02612-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundA dummy run was conducted to ensure the quality of intensity-modulated radiotherapy (IMRT) before registration in a randomized phase III study of elderly patients with newly diagnosed glioblastoma by the Japan Clinical Oncology Group 1910 (JCOG1910).MethodsAll 41 institutions enrolled in this study were required to report outlining that included gross tumor volume (GTV), clinical target volume (CTV), planning target volume (PTV), and treatment planning for one benchmark case. First, deviations in outlining were evaluated using the Dice similarity coefficient (DSC) and mean distance agreement (MDA), compared to reference targets delineated by the research secretariat. Second, the participating institutions were required to create treatment plans for arms A (40.05 Gy in 15 fractions) and B (25 Gy in 5 fractions) using IMRT techniques. The quality of the outlining and dose-volume criteria for each target and organs at risk were evaluated.ResultsSix institutions failed to adhere to the protocol and required revision due to insufficient GTV outlining, not considering anatomical barriers for CTV, and modifying PTV against protocols. Compared to the reference outlining, the means and standard deviations of DSC and MDA were 0.37 +/- 0.19 and 9.41 +/- 3.99 mm for GTV; 0.80 +/- 0.08 and 4.31 +/- 1.85 mm for CTV; and 0.83 +/- 0.05 and 4.23 +/- 1.45 mm for PTV, respectively. Regarding dose-volume criteria, 40 of the 41 institutions met the per-protocol limits; only one was within the acceptable limits.ConclusionsSeveral institutions demonstrated deviations in outlining that necessitated revisions. Thus, appropriate feedback and periodic sharing of information with participating institutions is necessary in the upcoming prospective JCOG1910 study.
引用
收藏
页数:9
相关论文
共 11 条
  • [1] A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)
    Arakawa, Yoshiki
    Sasaki, Keita
    Mineharu, Yohei
    Uto, Megumi
    Mizowaki, Takashi
    Mizusawa, Junki
    Sekino, Yuta
    Ono, Tomohiro
    Aoyama, Hidefumi
    Satomi, Kaishi
    Ichimura, Koichi
    Kinoshita, Manabu
    Ohno, Makoto
    Ito, Yoshinori
    Nishikawa, Ryo
    Fukuda, Haruhiko
    Nishimura, Yasumasa
    Narita, Yoshitaka
    BMC CANCER, 2021, 21 (01)
  • [2] A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)
    Yoshiki Arakawa
    Keita Sasaki
    Yohei Mineharu
    Megumi Uto
    Takashi Mizowaki
    Junki Mizusawa
    Yuta Sekino
    Tomohiro Ono
    Hidefumi Aoyama
    Kaishi Satomi
    Koichi Ichimura
    Manabu Kinoshita
    Makoto Ohno
    Yoshinori Ito
    Ryo Nishikawa
    Haruhiko Fukuda
    Yasumasa Nishimura
    Yoshitaka Narita
    BMC Cancer, 21
  • [3] Dummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402)
    Okamoto, Hiroyuki
    Murakami, Naoya
    Isohashi, Fumiaki
    Kasamatsu, Takahiro
    Hasumi, Yoko
    Iijima, Kotaro
    Nishioka, Shie
    Nakamura, Satoshi
    Nakamura, Mitsuhiro
    Nishio, Teiji
    Igaki, Hiroshi
    Nakayama, Yuko
    Itami, Jun
    Ishikura, Satoshi
    Nishimura, Yasumasa
    Toita, Takafumi
    RADIATION ONCOLOGY, 2019, 14 (1)
  • [4] Dummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402)
    Hiroyuki Okamoto
    Naoya Murakami
    Fumiaki Isohashi
    Takahiro Kasamatsu
    Yoko Hasumi
    Kotaro Iijima
    Shie Nishioka
    Satoshi Nakamura
    Mitsuhiro Nakamura
    Teiji Nishio
    Hiroshi Igaki
    Yuko Nakayama
    Jun Itami
    Satoshi Ishikura
    Yasumasa Nishimura
    Takafumi Toita
    Radiation Oncology, 14
  • [5] Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402)
    Okamoto, Hiroyuki
    Murakami, Naoya
    Isohashi, Fumiaki
    Kasamatsu, Takahiro
    Hasumi, Yoko
    Kobayashi, Hiroaki
    Ishikawa, Masayori
    Nakamura, Mitsuhiro
    Nishio, Teiji
    Igaki, Hiroshi
    Ishikura, Satoshi
    Yaegashi, Nobuo
    Mizowaki, Takashi
    Nishimura, Yasumasa
    Toita, Takafumi
    RADIOTHERAPY AND ONCOLOGY, 2023, 183
  • [6] Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy based-chemoradiation therapy for newly diagnosed glioblastoma: A multi-institutional study
    Kim, Nalee
    Lee, Joongyo
    Shin, Hyunju
    Shin, Jungwook
    Nam, Do-Hyun
    Lee, Jung-Il
    Seol, Ho Jun
    Kong, Doo-Sik
    Choi, Jung Won
    Chong, Kyuha
    Lee, Won Jae
    Chang, Jong Hee
    Kang, Seok-Gu
    Moon, Ju Hyung
    Cho, Jaeho
    Lim, Do Hoon
    Yoon, Hong in
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 47
  • [7] A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study)
    Kadota, Tomohiro
    Saito, Ryuta
    Kumabe, Toshihiro
    Mizusawa, Junki
    Katayama, Hiroshi
    Sumi, Minako
    Igaki, Hiroshi
    Kinoshita, Manabu
    Komori, Takashi
    Ichimura, Koichi
    Narita, Yoshitaka
    Nishikawa, Ryo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (12) : 1172 - 1175
  • [8] Single-arm confirmatory trial of postoperative concurrent chemoradiotherapy using intensity modulated radiation therapy for patients with high-risk uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402)
    Murakami, Naoya
    Isohashi, Fumiaki
    Hasumi, Yoko
    Kasamatsu, Takahiro
    Okamoto, Hiroyuki
    Nakamura, Kenichi
    Shibata, Taro
    Ito, Yoshinori
    Ishikura, Satoshi
    Nishimura, Yasumasa
    Yaegashi, Nobuo
    Toita, Takafumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (09) : 881 - 885
  • [9] Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508
    Yoshitoyo Kagami
    Kuniaki Itoh
    Kensei Tobinai
    Haruhiko Fukuda
    Kiyoshi Mukai
    Takaaki Chou
    Chikara Mikuni
    Tomohiro Kinoshita
    Noriyasu Fukushima
    Yoshio Kiyama
    Takayo Suzuki
    Tsuneo Sasaki
    Yuko Watanabe
    Kunihiro Tsukasaki
    Tomomitsu Hotta
    Masanori Shimoyama
    Michinori Ogura
    International Journal of Hematology, 2012, 96 : 74 - 83
  • [10] Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508
    Kagami, Yoshitoyo
    Itoh, Kuniaki
    Tobinai, Kensei
    Fukuda, Haruhiko
    Mukai, Kiyoshi
    Chou, Takaaki
    Mikuni, Chikara
    Kinoshita, Tomohiro
    Fukushima, Noriyasu
    Kiyama, Yoshio
    Suzuki, Takayo
    Sasaki, Tsuneo
    Watanabe, Yuko
    Tsukasaki, Kunihiro
    Hotta, Tomomitsu
    Shimoyama, Masanori
    Ogura, Michinori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (01) : 74 - 83